December 4th 2023
Your daily dose of the clinical news you may have missed.
November 29th 2023
The 5 leading advocacy groups said the safety of people with obesity is at risk and called on the FDA to change clinical trial inclusion requirements and expedite labeling changes.
November 28th 2023
Cardiovascular mortality has been increasing among middle-aged US adult since 2011; a new study looked at changes in CV risk factors by income level over the past 20 years.
November 20th 2023
Absolute risk assessment for CVD remains the corner-stone of clinical primary prevention efforts. The new AHA prediction models expand that foundation.
Cardiorenal Risk Estimates in T2D Mediated by Common Biomarker Response to Canagliflozin
Reduction in levels of 4 biomarkers was correlated with lower risk of composite cardiorenal outcomes in the CREDENCE trial, suggesting use of the panel to augment current risk assessment tools.
Daily Dose: Effect of Sotagliflozin on Heart Failure-Related Events
A daily dose of clinical news on Patient Care you may have missed.
Semaglutide 2.4 mg Could Reduce US Obesity by Half, Prevent 1.5 million CVD Events
More than 90 million adults in the US with overweight/obesity are candidates for weight loss treatment with semaglutide 2.4 mg, according to a new study.
NIH Designates Centers of Excellence to Improve Maternal Health Equity
The newly named centers across the country will work closely with communities to focus research on populations at greatest risk for perinatal morbidity and mortality.
Daily Dose: Daily Sugared Drink Intake & Risk of Hepatic Morbidity, Mortality in Postmenopausal Women
Amazon Pharmacy Announces Insulin Discounts with Automatic, Manufacturer-sponsored Coupons
Patients with diabetes will be able to save money when ordering insulin and commonly prescribed products, such as continuous glucose monitors and pumps.
Sotagliflozin Cut Risk by >50% for HF Rehospitalization and CV Death when Started Before Discharge
A post hoc analysis of the landmark SOLOIST-WFH trial supports avoiding delay in initiating the SGLT-2/1 inhibitor as part of guideline-recommended treatment.
Daily Dose: Diabetes- and CVD-Related Death Increase After 10-Year Decline
Daily Dose: Vegetarian Diet Boosts Optimal Drug Therapy in High-Risk CVD Patients
Insulin Prescription Fills Up Following Inflation Reduction Act Cap on Out-of-Pocket Costs
The new policy is helping people who are taking insulin save money and helping others to afford it in the first place, says a study coauthor from the USC Sol Price School of Public Policy .
Mean Weight Loss with Tirzepatide Reaches 26% Across 2 Pivotal Phase 3 Clinical Trials
In adults with obesity or overweight plus comorbidities but without T2D once-weekly tirzepatide was associated with significant and durable weight loss vs placebo.
Vegetarian Diet May Augment Effects of Optimal Drug Therapy in Patients at High Risk of CVD
Reductions in LDL-C, HbA1c, and body weight were associated with a variety of vegetarian diets in participants with or at high risk for cardiovascular disease.
Social Determinants of Health and Prevention of Cardiovascular Disease
Methods proven to prevent ASCVD may fall short in certain populations if the impacts of SDOH are not closely monitored. The ACC/AHA provide considerations for 7 health domains.
Diabetes- and CVD-Related Mortality Rise after Steady 10-Year Decline
Since 2014, the age-adjusted mortality rate for diabetes and CVD has increased by 1% after an overall decline between 1999 and 2019, new research finds.
When Statin Guidelines Collide: 5 Questions on 2 Approaches to Primary CVD Prevention
Guidelines on primary ASCVD prevention from the USPSTF and the AHA/ACC/Multisociety differ on why and when to initiate a statin. Try the 5-question quiz.
Daily Dose: The BMI vs Body Fat Debate
Your daily dose of clinical news you may have missed.
Prescription Digital Behavioral Therapeutic for Type 2 Diabetes Wins FDA Marketing Clearance
AspyreRx™, prescribed in 90-day increments, resulted in a mean HbA1c reduction of 1.3% at 180 days in 1 out of 2 phase 3 trial participants. A Q4 launch is anticipated.
Daily Dose: T2D Raises Risk for Hepatic Decompensation, Hepatocellular Carcinoma in Patients with NAFLD
BMI vs body fat; menopause and martinis; statin guidelines collide; +2 - The Five for Friday
Is BMI or body fat a better estimate of obesity?; spoiler: older women do drink ETOH; USPSTF vs ACC/AHA; plus no more opioids for LBP and a primer on migraine meds.
The BMI vs Body Fat Debate: Study Suggests One-Third of People with Normal BMI are Obese
In Israel, where 60% of adults are overweight, new research prompts investigators to suggest that % body fat should replace BMI as the gold standard measure of obesity.
Menopause and ETOH: Beware the Tipping Point
Binge drinking among women going through menopause has been on the rise, research indicates, making clinical inquiry in this population particularly important.
In Patients with NAFLD, Type 2 Diabetes Significantly Ups Risk for Hepatic Decompensation, Hepatocellular Carcinoma
In patients with NAFLD, type 2 diabetes was found to be an independent predictor of both hepatic decompensation and incident HCC, according to meta-analysis authors. .
Expert to Primary Care: Use these "ABCs" to Manage Obesity and T2D
The importance of avoiding judgement, monitoring behavior, and cardiovascular risk prevention in primary care are discussed, here.
Inclisiran Label Expanded to Include Primary Prevention Population
The expanded indication widens the patient population eligible for the novel siRNA therapy to include high-risk patients on maximum statin Rx who have not had a CV event.
Statins Appear Beneficial for CV Outcomes in Primary Prevention Patients with HTN without CVD or Diabetes
In a study of over 26 000 participants, statin use was associated with reduced risk for all-cause and CV mortality compared to placebo.
Daily Dose: Loneliness and CVD Risk in Patients with Diabetes
Daily Dose: Childhood Glycemic Measures as Predictors of Diabetes-Related Complications
Treating Obesity & T2D: Experts Say Simultaneous, Early Intervention is Key
Early intervention is crucial to help prevent complications in patients with obesity and type 2 diabetes. Two experts explain more, here.
Daily Dose: Pegozafermin in Patients with NASH
Loneliness Linked to Greater Risk for CVD in Individuals with Diabetes
The predictive value of loneliness for cardiovascular disease in patients with diabetes was stronger than traditional lifestyle risk factors in large UK Biobank analysis.
2 Clarke Drive Cranbury, NJ 08512